S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.08 (+0.07%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.66 (+4.81%)
AMD   175.62 (-0.51%)
BABA   76.39 (+0.57%)
T   16.77 (-0.18%)
F   12.19 (+0.41%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.56 (+0.80%)
DIS   108.13 (+0.36%)
AMC   4.52 (+1.80%)
PFE   27.42 (-1.22%)
PYPL   59.23 (+0.12%)
XOM   103.92 (+0.08%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.08 (+0.07%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.66 (+4.81%)
AMD   175.62 (-0.51%)
BABA   76.39 (+0.57%)
T   16.77 (-0.18%)
F   12.19 (+0.41%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.56 (+0.80%)
DIS   108.13 (+0.36%)
AMC   4.52 (+1.80%)
PFE   27.42 (-1.22%)
PYPL   59.23 (+0.12%)
XOM   103.92 (+0.08%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.08 (+0.07%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.66 (+4.81%)
AMD   175.62 (-0.51%)
BABA   76.39 (+0.57%)
T   16.77 (-0.18%)
F   12.19 (+0.41%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.56 (+0.80%)
DIS   108.13 (+0.36%)
AMC   4.52 (+1.80%)
PFE   27.42 (-1.22%)
PYPL   59.23 (+0.12%)
XOM   103.92 (+0.08%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.08 (+0.07%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.66 (+4.81%)
AMD   175.62 (-0.51%)
BABA   76.39 (+0.57%)
T   16.77 (-0.18%)
F   12.19 (+0.41%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.56 (+0.80%)
DIS   108.13 (+0.36%)
AMC   4.52 (+1.80%)
PFE   27.42 (-1.22%)
PYPL   59.23 (+0.12%)
XOM   103.92 (+0.08%)

Supreme Court revives claims that SuperValu, Safeway overcharged governments for generic drugs


The Supreme Court is seen in Washington, on Nov. 5, 2020. The Supreme Court has unanimously revived whistleblower lawsuits claiming that supermarket and pharmacy chains SuperValu and Safeway overcharged government health-care programs for prescription drugs by hundreds of millions of dollars. (AP Photo/J. Scott Applewhite, File)

WASHINGTON (AP) — The Supreme Court on Thursday unanimously revived whistleblower lawsuits claiming that supermarket and pharmacy chains SuperValu and Safeway overcharged government health-care programs for prescription drugs by hundreds of millions of dollars.

The decision gives the whistleblowers another chance to pursue their claims that the companies defrauded the Medicare and Medicaid programs when they reported retail prices for generic prescription drugs, even though they had mainly been sold to customers at deeply discounted prices.

The cases stem from the companies’ effort to match a 2006 decision by Walmart to offer 30-day supplies of many generic drugs for $4.

SuperValu and Safeway matched the discounted price at their pharmacies, but they reported to the federal and various state governments a much higher “usual and customary” price when seeking reimbursement.

The 7th U.S. Circuit Court of Appeals dismissed the suits against both companies, holding that their decisions to report the higher prices were “not objectively unreasonable” under the federal False Claims Act.

Writing for the high court Thursday, Justice Clarence Thomas wrote that the appeals court applied the wrong standard. “What matters for an FCA case is whether the defendant knew the claim was false,” Thomas wrote.

An expert for the whistleblower in the Safeway lawsuit testified that the company received $127 million more than it would have gotten had it reported the discounted price, according to court papers.

In the case against SuperValu, the whistleblower said the company matched Walmart’s discounted price 6.3 million times over 11 years, according to court papers.

A lawyer for the company told the justices at arguments in April that figuring out the correct price to report is harder than it seems.

But Thomas said the whistleblowers had amassed evidence showing that executives believed the discounted prices should have been reported and took steps to hide the lower prices from state and federal authorities.

The justices did not issue a final ruling on the claims, which will be left for lower courts to sort out.

→ Blue Chips And Billionaires Quietly Investing In "The New Oil" (From Edge On The Street) (Ad)

Where should you invest $1,000 right now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Featured Articles and Offers

Search Headlines: